Onyx Biotec Q4 FY26 Results: Announced May 14 2026 Pharmaceuticals – Oncology and Injectables
- May 15, 2026
- Posted by: Kashish Aggarwal
- Category: News
Onyx Biotec results were announced on May 14, 2026, at the company’s board meeting. Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 15 crore. Pharmaceutical and biotech company. Results filed with BSE on May 14, 2026. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.
Click Here – Get Free Investment Predictions
Onyx Biotec Q4 FY26 Key Financial Highlights
| Metric | Q4 FY26 | Comparison |
|---|---|---|
| PAT (Net Profit) | Rs 1 crore | Q4 FY26 |
| Revenue from Operations | Rs 15 crore | Q4 FY26 |
| Ticker | ONYXBIO | Sector: Pharmaceuticals – Oncology and Injectables |
Screen the best stocks on the Univest Screener.
Onyx Biotec Performance Analysis
The company results reflect the company’s operational performance during the January to March 2026 quarter. the company results announced May 14, 2026. The company manufactures oncology injectables, lyophilized formulations, and specialty pharmaceutical products for institutional buyers. Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.
The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.
Onyx Biotec FY27 Outlook
Post Onyx Biotec, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Pharmaceuticals – Oncology and Injectables space. The Onyx Biotec results demonstrate the company’s execution capabilities. Track Onyx Biotec updates on the Univest Screener for analyst views and FY27 earnings estimates.
Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.
Frequently Asked Questions on Onyx Biotec Q4 FY26 Results
What is Onyx Biotec Q4 FY26 PAT?
Ans. Onyx Biotec Q4 FY26 PAT of Rs 1 crore (results declared May 14, 2026). Q4 FY26 PAT approximately Rs 1 crore on revenue approximately Rs 15 crore. Pharmaceutical and biotech company. Results filed with BSE on May 14, 2026..
When did Onyx Biotec announce Q4 FY26 results?
Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.
What is the FY27 outlook for Onyx Biotec?
Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Pharmaceuticals – Oncology and Injectables sector. Track live updates on the Univest Screener.
Where can I track Onyx Biotec Q4 FY26 live data?
Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.
